124 related articles for article (PubMed ID: 37598012)
1. Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features.
Kim DK; Kim JH; Park JY; Gwon YN; Kim KM; Yang WJ; Doo SW; Song YS
Clin Genitourin Cancer; 2024 Feb; 22(1):e53-e65.e1. PubMed ID: 37598012
[TBL] [Abstract][Full Text] [Related]
2. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder.
Rahman SN; Lokeshwar SD; Syed JS; Javier-Desloges JF; Press BH; Choksi AU; Rajwa P; Pradere B; Ploussard G; Kim JW; Monaghan TF; Renzulli JR; Shariat SF; Leapman MS
Urol Oncol; 2023 Feb; 41(2):107.e1-107.e8. PubMed ID: 36481253
[TBL] [Abstract][Full Text] [Related]
3. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
[TBL] [Abstract][Full Text] [Related]
4. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
[TBL] [Abstract][Full Text] [Related]
7. Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Pak JS; Haas CR; Anderson CB; DeCastro GJ; Benson MC; McKiernan JM
Urol Oncol; 2021 Nov; 39(11):787.e9-787.e15. PubMed ID: 33865688
[TBL] [Abstract][Full Text] [Related]
8. Impact of Neoadjuvant Chemotherapy on Pathologic Downstaging in Patients With Variant Histology Undergoing Radical Cystectomy.
Campbell RA; Khanna A; Boorjian SA; Knorr J; Cox R; Nicholas M; Cheville J; Sharma V; Murthy PB; Tarrell R; Thapa P; Tollefson MK; Thompson RH; Frank I; Karnes RJ; Haber GP; Lee B
Clin Genitourin Cancer; 2024 Apr; 22(2):157-163.e1. PubMed ID: 38008690
[TBL] [Abstract][Full Text] [Related]
9. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
[TBL] [Abstract][Full Text] [Related]
10. Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database.
Fu M; Klose C; Sparks A; Whalen M
Clin Genitourin Cancer; 2022 Apr; 20(2):e135-e139. PubMed ID: 34961704
[TBL] [Abstract][Full Text] [Related]
11. Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?
Berg S; D'Andrea D; Vetterlein MW; Cole AP; Fletcher SA; Krimphove MJ; Marchese M; Lipsitz SR; Sonpavde G; Noldus J; Shariat SF; Kibel AS; Trinh QD; Mossanen M
Cancer; 2019 May; 125(9):1449-1458. PubMed ID: 30620387
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological factors in bladder cancer for cancer-specific survival outcomes following radical cystectomy: a systematic review and meta-analysis.
Zhang L; Wu B; Zha Z; Qu W; Zhao H; Yuan J
BMC Cancer; 2019 Jul; 19(1):716. PubMed ID: 31324162
[TBL] [Abstract][Full Text] [Related]
13. Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy.
Hwang EC; Sathianathen NJ; Imamura M; Kuntz GM; Risk MC; Dahm P
Cochrane Database Syst Rev; 2019 May; 5(5):CD013336. PubMed ID: 31111956
[TBL] [Abstract][Full Text] [Related]
14. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis.
Cacciamani GE; Ghodoussipour S; Mari A; Gill KS; Desai M; Artibani W; Gill PS; Shariat SF; Gill IS; Djaladat H
J Urol; 2020 Oct; 204(4):649-660. PubMed ID: 32105187
[TBL] [Abstract][Full Text] [Related]
15. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
Gabrielson AT; Daniels MJ; Rowe J; Alam R; Lee EJ; Matoso A; De Felice A; Hahn N; Hoffman-Censits J; Bivalacqua TJ; Kates M
Urol Oncol; 2022 Apr; 40(4):164.e9-164.e16. PubMed ID: 35045949
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy.
Mori K; Abufaraj M; Mostafaei H; Quhal F; Karakiewicz PI; Briganti A; Kimura S; Egawa S; Shariat SF
J Urol; 2020 Dec; 204(6):1129-1140. PubMed ID: 32716694
[TBL] [Abstract][Full Text] [Related]
17. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
[TBL] [Abstract][Full Text] [Related]
20. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension.
Murthy PB; Naidu S; Davaro F; Spiess PE; Zemp L; Poch M; Jain R; Vosoughi A; Grass GD; Yu A; Sexton WJ; Gilbert SM; Li R
Curr Oncol; 2023 Mar; 30(3):3223-3231. PubMed ID: 36975458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
